Table 2.
Term | Data Source | Method | (v, x) Level | ||||
---|---|---|---|---|---|---|---|
(0,0) | (0,1) | (1,0) | (1,1) | ||||
|
RV144 | Structural MLR | Figure 1 | Figure 1 | 0.01 | 0.01 | |
|
RV144 | From above2 | Not shown | NS | NS | NS | |
F̂*(s1|x) | HVTN 1003 | Empirical NPMLEs | Figure 2 | Figure 2 | Figure 2 | Figure 2 | |
Ĥ*(x) for x = 0 (CC) and x = 1 (CT/TT) | Host genetics database | Frequency of CC, CT/TT in n = 131 Black South Africans | 0.51 | 0.49 | 0.51 | 0.49 | |
| |||||||
ŵInc(t = 39|x) numer: | HVTN 503 trial in RSA (2007–2013) (Gray et al., 2014) | IPW Kaplan-Meier NPMLEs | 0.1214 | 0.1214 | 0.1214 | 0.1214 | |
ŵInc(t = 39|x) denom: | RV144 | IPW Aalen-Johansen | 0.0070 | 0.012 | 0.0070 | 0.012 | |
ŵInc(t = 39|x) | 17.3 | 10.08 | 17.3 | 10.08 | |||
| |||||||
ŵV(t = 39, v|x) numer: | HIV sequence database | Frequency of v = 0 (169K) and v = 1 (X169K) in the RSA IPW Aalen-Johansen + database | 0.605 | 0.605 | 0.405 | 0.405 | |
ŵV(t = 39, v|x) denom: | RV144 | 0.706 | 0.766 | 0.336 | 0.206 | ||
ŵV(t = 39, v|x) | 0.86 | 0.79 | 1.22 | 2.03 |
Estimated as 0.0 because (95% CI = −2.58 to 0.33) and the belief that the vaccine did not increase infection risk.
Estimated as part of the method for estimating (details in Supplementary Appendix B).
Because HVTN 100 has not yet completed, the data from RV144 were used.
The estimates are the same for x = 0 and x = 1 because data on X were not available in the HVTN 503 trial.
The estimates are the same for v = 0 and v = 1 because data on X were not available in HVTN 503; the estimates are empirical fractions from 254 HIV-1 sequences of South Africans in the LANL database from 2008 to 2013.
Initial estimates from RV144 (IPW Aalen-Johansen) and final estimates using empirical fractions from 207 HIV-1 sequences of Thais in the LANL database from 2003 to 2009 (See Supplementary Appendix B).